Undisclosed immuno-inflammation therapeutic / Ampersand Biomedicines - LARVOL DELTA

Ampersand Biomedicines Raises Series B Financing and Highlights Pipeline Advancements (GlobeNewswire) - "Ampersand Biomedicines...today announced it has secured $65 million in Series B funding from investors including Ampersand’s founder, Flagship Pioneering, Eli Lilly & Company, and several additional new investors. In addition, the company announced the advancement of two lead programs and a second discovery partnership in obesity...The funding will also drive the acceleration of Ampersand’s initial pipeline of impactful programs, including one in immuno-inflammation and another in immuno-oncology, both of which are planned to enter IND-enabling studies in 2025."

Financing • Preclinical • Immunology • Obesity • Oncology